Search | Clinical Trials Finder

Conditions: Diabetes or With New Hyperglycemia
Interventions: Glucommander, Standard insulin infusion algorithm; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington

Conditions: Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
Interventions: Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules); Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy
Interventions: Low dose Regular Insulin, High dose Regular insulin; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 35 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 1 Diabetes
Interventions: Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin; Drug
Lead sponsor: Portal Diabetes, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Volunteers
Interventions: rHuPH20, Insulin Human Injection, Insulin Lispro Injection; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Wound Healing, Diabetes
Interventions: Pulsatile Intravenous Insulin Therapy; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Parkinson Disease
Interventions: INS-GSH, Matched Placebos; Drug
Lead sponsor: Gateway Institute for Brain Research; Industry
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more

Conditions: Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Insulin (Humulin® R U-100), Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more

Conditions: Healthy
Interventions: Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 36 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions: Leptin, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type I Diabetes
Interventions: Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R); Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more

Conditions: Diabetes
Interventions: Wosulin R, Actrapid; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions: Insulin, intranasal, Placebo, intranasal; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin human, insulin lispro, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions: r-metHuLeptin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: 67.5 mg oral insulin crystals daily, 500mg oral insulin crystals every other week; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 13 more

Conditions: Diabetes
Interventions: Wosulin N, Novolin N; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Prediabetes, Healthy (Controls)
Interventions: Ketone Monoester (KE), Placebo; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Hypoglycemia
Interventions: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 20 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Type 2 Diabetes, Hyperglycemia
Interventions: sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus; Drug
Lead sponsor: Guillermo Umpierrez, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Regular Insulin, Humalog; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

SNIFF - Combo INI+EMPA Trial

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

Intranasal Insulin for the Treatment of HAND

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?

Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery